Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

26.39
Delayed Data
As of Sep 23
 -0.21 / -0.79%
Today’s Change
16.75
Today|||52-Week Range
41.77
-20.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$502.4M

Company Description

Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It focuses on the following disease targets: Hepatitis C virus, Hepatitis B virus, Non-alcoholic Steatohepatitis, and Respiratory syncytial virus. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Contact Information

Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown Massachusetts 02472
P:(617) 607-0800
Investor Relations:
(617) 607-0710

Employees

Shareholders

Other institutional40.90%
Individual stakeholders35.68%
Mutual fund holders31.54%

Top Executives

Jay R. LulyPresident, CEO & Class I Director
Paul J. MellettCFO, Senior VP-Finance & Administration
Yat Sun OrChief Scientific Officer, Senior VP-R&D
Nathalie AddaChief Medical Officer & Senior Vice President
Nathaniel S. GardinerSecretary, Senior Vice President & General Counsel